G-protein coupled receptor 34 activates Erk and phosphatidylinositol 3-kinase/Akt pathways and functions as alternative pathway to mediate p185Bcr–Abl-induced transformation and leukemogenesis

References

• Nieborowska-Skorska M, Wasik MA, Slupianek A, et al. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med 1999;189:1229–11242.
   PubMed Web of Science ®Google Scholar
• Steelman LS, Pohnert SC, Shelton JG, et al. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004;18:189–218.
   PubMed Web of Science ®Google Scholar
• Wu LX, Xu JH, Zhang KZ, et al. Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin. Leukemia 2008;22:1402–1409.
   PubMed Web of Science ®Google Scholar
• Yu W, Sun X, Clough N, et al. Abi1 gene silencing by short hairpin RNA impairs Bcr–Abl-induced cell adhesion and migration in vitro and leukemogenesis in vivo. Carcinogenesis 2008;29:1717–1724.
   PubMed Web of Science ®Google Scholar
• Cortez D, Kadlec L, Pendergast AM. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol 1995;15:5531–5541.
   PubMed Web of Science ®Google Scholar
• Million RP, Van Etten RA. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood 2000;96:664–670.
   PubMed Web of Science ®Google Scholar
• Sirard C, Laneuville P, Dick JE. Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. Blood 1994;83:1575–1585.
   PubMed Web of Science ®Google Scholar
• Amarante-Mendes GP, McGahon AJ, Nishioka WK, et al. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene 1998;16: 1383–1390.
   PubMed Web of Science ®Google Scholar
• Morse HC 3rd, Anver MR, Fredrickson TN, et al.;Hematopathology subcommittee of the Mouse Models of Human Cancers Consortium. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood 2002;100:246–258.
   PubMed Web of Science ®Google Scholar
• Sugo T, Tachimoto H, Chikatsu T, et al. Identification of a lysophosphatidylserine receptor on mast cells. Biochem Biophys Res Commun 2006;341:1078–1087.
   PubMed Web of Science ®Google Scholar
• New DC, Wu K, Kwok AW, et al. G protein-coupled receptor-induced Akt activity in cellular proliferation and apoptosis. FEBS J 2007;274:6025–6036.
   PubMed Web of Science ®Google Scholar
• Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011;10:47–60.
   PubMed Web of Science ®Google Scholar
• Engemaier E, Römpler H, Schöneberg T, et al. Genomic and supragenomic structure of the nucleotide-like G-protein-coupled receptor GPR34. Genomics 2006;87:254–264.
   PubMed Web of Science ®Google Scholar
• Iwashita M, Makide K, Nonomura T, et al. Synthesis and evaluation of lysophosphatidylserine analogues as inducers of mast cell degranulation. Potent activities of lysophosphatidylthreonine and its 2-deoxy derivative. J Med Chem 2009;52:5837–5863.
   PubMed Web of Science ®Google Scholar
• Bédard A, Tremblay P, Chernomoretz A, et al. Identification of genes preferentially expressed by microglia and upregulated during cuprizone-induced inflammation. Glia 2007;55:777–789.
   PubMed Web of Science ®Google Scholar
• Qin Y, Verdegaal EM, Siderius M, et al. Quantitative expression profiling of G protein-coupled receptors (GPCRs) in metastatic melanoma: the constitutively active orphan GPCR GPR18 as novel drug target. Pigment Cell Melanoma Res 2011;24:207–218.
   PubMed Web of Science ®Google Scholar
• Baens M, Finalet Ferreiro J, Tousseyn T, et al. t(X;14)(p11.4;q32.33) is recurrent in marginal zone lymphoma and up-regulates GPR34. Haematologica 2012;97:184–188.
   PubMed Web of Science ®Google Scholar
• Hamoudi RA, Appert A, Ye H, et al. Differential expression of NF-kappaB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism. Leukemia 2010;24:1487–1497.
   PubMed Web of Science ®Google Scholar
• Frasch SC, Zemski-Berry K, Murphy RC, et al. Lysophospholipids of different classes mobilize neutrophil secretory vesicles and induce redundant signaling through G2A. J Immunol 2007;178: 6540–6548.
   PubMed Web of Science ®Google Scholar
• Yu W, Sun X, Tang H, et al. Inhibition of class II phosphoinositide 3-kinase gamma expression by p185(Bcr-Abl) contributes to impaired chemotaxis and aberrant homing of leukemic cells. Leuk Lymphoma 2010;51:1098–1107.
   PubMed Web of Science ®Google Scholar
• Ruan GR, Qin YZ, Chen SS, et al. Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia. Leuk Res 2006;30:1159–1165.
   PubMed Web of Science ®Google Scholar
• New DC, Wu K, Kwok AW, et al. G protein-coupled receptor-induced Akt activity in cellular proliferation and apoptosis. FEBS J 2007;274:6025–6036.
   PubMed Web of Science ®Google Scholar
• Tang SY, Xie H, Yuan LQ, et al. Apelin stimulates proliferation and suppresses apoptosis of mouse osteoblastic cell line MC3T3–E1 via JNK and PI3-K/Akt signaling pathways. Peptides 2007;28:708–718.
   PubMed Web of Science ®Google Scholar
• Liebscher I, Müller U, Teupser D, et al. Altered immune response in mice deficient for the G protein-coupled receptor GPR34. J Biol Chem 2011;286:2101–2110.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Akasaka T, McPhail E, et al. t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth. Blood 2012;120:3949–3957.
   PubMed Web of Science ®Google Scholar
• Zebedin E, Freissmuth M, Sexl V. Signal interception-based therapies—a double-edged sword in Bcr/abl-induced malignancies? Leuk Lymphoma 2008;49:620–624.
   PubMed Web of Science ®Google Scholar
• Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 1997;16:6151–6161.
   PubMed Web of Science ®Google Scholar
• Pendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993;75:175–185.
   PubMed Web of Science ®Google Scholar
• Puil L, Liu J, Gish G, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994;13:764–773.
   PubMed Web of Science ®Google Scholar
• Stanglmaier M, Warmuth M, Kleinlein I, et al. The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains. Leukemia 2003;17:283–289.
   PubMed Web of Science ®Google Scholar
• Roumiantsev S, de Aos IE, Varticovski L, et al. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood 2001;97:4–13.
   PubMed Web of Science ®Google Scholar